Guangzhou Hanfang Pharmaceutical Launches USPGrade MCT Supply

Domestically developed excipient breaks foreign monopolies, meets global pharmacopeia standards

GUANGZHOU, China – October 24, 2026 – Guangzhou Hanfang Pharmaceutical Company Limited, a leading Chinese supplier of USP-grade medium chain triglycerides and high-end pharmaceutical lipid excipients, today announced the full commercial launch of its USP-compliant medium chain triglyceride (MCT) raw material for global pharmaceutical and health product clients. The product is designed to address the core pain point of global pharmaceutical manufacturers seeking reliable, cost-effective, domestically produced high-end lipid excipients, with core advantages including high purity, low impurity levels, and green production processes. Through this launch, the company aims to expand its global footprint in the high-end pharmaceutical lipid excipient market, supporting clients across more than 30 countries and regions. The new product is now available for global pre-orders, with mass production and global shipping starting immediately.

Core Technical Breakthroughs and Product Advantages

The USP-grade medium chain triglyceride product is built on the company’s proprietary integrated green technology, with key advantages as follows:
1. Domestic monopoly breakthrough: The product achieves a leap in the localization rate of high-end pharmaceutical lipid excipients from 10% to 90%, ending the long-term reliance on imported MCT for domestic and global pharmaceutical clients.
2. Green production process: The company adopts the proprietary supercritical CO₂ extraction, membrane separation, and chromatography separation integrated technology, replacing traditional polluting production processes to reduce environmental impact and improve product consistency.
3. High purity and compliance: The product meets USP grade requirements, with strict quality control to ensure low impurity levels suitable for injectable, oral, and special medical application scenarios.
4. Rich intellectual property support: The product is backed by the company’s more than 240 patents accumulated as of 2025, with core technology developed at the national engineering research center for pharmaceutical manufacturing process technology and new drug creation.

Global Compliance and Market Access

To meet global market entry requirements, the USP-grade medium chain triglyceride product has obtained multiple international regulatory certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. The product complies with the regulatory requirements of major markets in the European Union, North America, Asia Pacific, and Latin America, and can be widely used in chemical drugs, biologic drugs, traditional Chinese medicine, high-end preparations, health products, and special medical food scenarios. The company’s products are currently sold to more than 30 countries and regions, serving more than 1000 clients including well-known enterprises such as B. Braun Company, AstraZeneca, Sichuan Kelun Pharmaceutical, Qilu Pharmaceutical, and Chenxin Pharmaceutical.

Supply and Customization Services

The USP-grade medium chain triglyceride product is now available for global pre-orders through the company’s official website, global authorized distributors, and direct sales channels. Mass production and global shipping have started immediately, with standard delivery lead times for bulk orders ranging from 4 to 6 weeks. In addition to standard product specifications, the company also provides customized processing services for global enterprise clients, including adjustments to product purity, packaging specifications, and application-specific formulation optimization, to meet the diverse needs of different industries and projects.

Management Statement

Xu Wendong, General Manager of Guangzhou Hanfang Pharmaceutical Company Limited, and deputy director of the national engineering research center, stated that the launch of the USP-grade medium chain triglycerides marks a key milestone in the company’s mission to advance technological self-reliance in the biopharmaceutical sector and resolve bottleneck technologies that affect the security of the pharmaceutical supply chain. He added that the company is committed to providing global clients with reliable, internationally compliant lipid excipients that meet the highest industry standards, while continuing to invest in R&D to expand its product portfolio.

Industry Background and Strategic Layout

Global demand for high-purity, compliant pharmaceutical lipid excipients has grown steadily as the global biologic and generic drug sectors expand, with many manufacturers seeking alternative suppliers to reduce reliance on single-source imports. As a national-level specialized and sophisticated little giant enterprise, Guangzhou Hanfang Pharmaceutical has long focused on breaking foreign monopolies in high-end pharmaceutical lipid excipients, and the launch of the USP-grade MCT product aligns with the company’s strategic layout to support the global pharmaceutical supply chain with reliable domestic alternatives.

Future Plans

Moving forward, Guangzhou Hanfang Pharmaceutical will continue to deepen its R&D investment in high-end pharmaceutical lipid excipients, expand its global sales and service network, and obtain additional regulatory approvals to serve more clients in emerging markets. The company will also continue to optimize its production processes to improve product quality and reduce costs, providing more competitive solutions for global pharmaceutical and health product clients.

Company Profile

Guangzhou Hanfang Pharmaceutical Company Limited was established in 1998, and is a core state-owned enterprise under Guangzhou Pharmaceutical Holdings Limited, a Fortune 500 company. The company focuses on the R&D, production, and sales of raw materials and pharmaceutical lipid excipients, health products, and technical services, with headquarters in Guangzhou, China. It owns the only national engineering research center for traditional Chinese medicine engineering technology in China, the Guangdong Provincial Key Laboratory of Pharmaceutical Lipids, and has obtained more than 240 patents as of 2025. The company’s mission is to advance technological self-reliance in the biopharmaceutical sector, resolve bottleneck technologies, and safeguard the security of the national pharmaceutical supply chain, while inheriting and innovating traditional Chinese medicine to protect human health. More information is available at the company’s official website.

FAQ

Q: What regulatory certifications does the USP-grade medium chain triglyceride product hold?
A: The product holds EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI certifications, meeting the regulatory requirements of major global pharmaceutical markets.
Q: Does Guangzhou Hanfang Pharmaceutical provide customized MCT solutions for clients?
A: Yes, the company offers customized processing services, including adjustments to product purity, packaging specifications, and application-specific formulation optimization, to meet diverse client needs.
Q: How many countries and regions does the company serve?
A: The company’s products are currently sold to more than 30 countries and regions, serving over 1000 clients across the pharmaceutical, health product, and research sectors.

Contact Us

Official Website: https://byshanhanfang.com/
Factory Address: No. 8 Wenquan Avenue, Wenquan Town, Conghua District, Guangzhou, Guangdong, China
Headquarters Address: No. 134 Jiangnan Avenue Middle, Haizhu District, Guangzhou, Guangdong, China